Related Experiment Video
Updated: Aug 5, 2026
A Method for High Fidelity Optogenetic Control of Individual Pyramidal Neurons In vivo
Published on: September 2, 2013
Engineering a 660 nm-Responsive Optogenetic Inducer of Pyroptosis for Precision Cancer Therapy
Mengkai Zhang1, Zhichao Li1, Yonghao Ma2
1Medical Innovation Technology Transformation Center, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Institute for Advanced Study, Synthetic Biology Research Center, Shenzhen University, Shenzhen, People's Republic of China.
Researchers developed PyroRACS, a novel optogenetic tool for precise control of pyroptosis, a promising cancer therapy. This innovation enables targeted tumor cell killing with reduced systemic damage and improved viral vector production.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Pyroptosis is a promising anticancer strategy, but its uncontrolled induction poses risks.
- Lack of precise spatiotemporal control limits pyroptosis-based therapies.
- Developing genetic tools for controlled pyroptosis is crucial for clinical translation.
Purpose of the Study:
- To develop a novel bioorthogonal optogenetic tool for precise spatiotemporal control of pyroptosis.
- To enable tunable pyroptosis induction independent of endogenous pathways.
- To advance pyroptosis-based precision oncology therapeutics.
Main Methods:
- Development of PyroRACS, a red-light-activatable Cre-ON genetic switch (RACS).
- RACS drives expression of the gasdermin D N-terminal domain for pyroptosis induction.
- Validation in multiple cell lines and a tumor-bearing mouse model.
Main Results:
- PyroRACS demonstrated robust and controllable pyroptosis induction in vitro.
- Selective cancer cell ablation with precise spatiotemporal resolution was achieved.
- Effective tumor suppression with no detectable systemic toxicity in vivo.
Conclusions:
- PyroRACS offers a novel optogenetic tool for precise pyroptosis manipulation.
- This tool facilitates fundamental research in pyroptosis.
- PyroRACS advances the development of pyroptosis-based precision oncology therapeutics.
